Pro MedicusASX:PME +3.58%98 ROA % is 78.49% as of Dec. 2025, which is 202% above its 10-year median of 25.99. GuruFocus rates ASX:PME with a GF Score™ of 98/100 and a GF Value™ of A$244.95 (Modestly Undervalued). The stock has 1 warning sign investors should review. Among 686 Healthcare Providers & Services companies, Pro Medicus ranks better than 99.56% on this metric.
ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. Pro Medicus's annualizedNet Income for the quarter that ended in Dec. 2025 was A$342.4 Mil.
Pro Medicus's average Total Assets over the quarter that ended in Dec. 2025 was A$436.3 Mil. Therefore, Pro Medicus's annualized ROA % for the quarter that ended in Dec. 2025 was 78.49%.
The historical rank and industry rank for Pro Medicus's ROA % or its related term are showing as below:
ASX:PME'
s ROA % Range Over the Past 10 Years
Min: 18.42 Med: 25.99 Max: 60.34
Current: 60.34
During the past 13 years, Pro Medicus's highest ROA % was 60.34%. The lowest was 18.42%. And the median was 25.99%.
ASX:PME's ROA % is ranked better than 99.56% of 686
companies
in the Healthcare Providers & Services industry
Industry Median: 1.75
vs ASX:PME: 60.34
Pro Medicus (ASX:PME) ROA % Explanation
ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A banks ROA % is typically well under 2%.
Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:
Note:
The Net Income data used here is two times the semi-annual (Dec. 2025) net income data. The Revenue data used here is two times the semi-annual (Dec. 2025) revenue data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.
E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.
Pro Medicus ROA % Related Terms
Pro Medicus ROA % Historical Data
* Premium members only.
The historical data trend for Pro Medicus's ROA % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Health Information Services subindustry, Pro Medicus's ROA %, along with its competitors' market caps and ROA % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pro Medicus ROA % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Pro Medicus's ROA % distribution charts can be found below:
* The bar in red indicates where Pro Medicus's ROA % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is two times the semi-annual (Dec. 2025) net income data.
ROA % is displayed in the 30-year financial page.
Pro Medicus (ASX:PME) has a ROA % of 78.49% as of Dec. 2025. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on Pro Medicus and its competitors. This is 202% above median its historical median of 25.99. Over the past decade, Pro Medicus' ROA % has ranged from 18.42 to 60.34. According to the industry distribution chart, Pro Medicus ranks #3 out of 686 companies in the Healthcare Providers & Services industry, placing it in the top 0.40000000000001%.
Is Pro Medicus' ROA % too high?
Pro Medicus' current ROA % of 78.49% is 202% above median its 10-year median of 25.99. Over the past 10 years, this metric has ranged from a low of 18.42 to a high of 60.34. The Healthcare Providers & Services industry median ROA % is 1.75. Pro Medicus' value of 78.49% is 4385.1% above this industry median. Based on the distribution chart, Pro Medicus ranks #3 out of 686 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers. Overall, Pro Medicus has a GF Score™ of 98/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Pro Medicus' ROA % compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, Pro Medicus ranks #3 out of 686 companies for ROA %. This places Pro Medicus in the top 0% of its industry — outperforming the majority of peers. The industry median ROA % is 1.75. Pro Medicus' value of 78.49% is 4385.1% above this benchmark. Historically, Pro Medicus' own ROA % has ranged from 18.42 to 60.34 over the past decade. While the company's 10-year median is 25.99 vs. the industry median of 1.75, Pro Medicus has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROA % for a Healthcare Providers & Services company?
The median ROA % among Healthcare Providers & Services companies is 1.75, based on 686 companies in the industry. Companies in the top quartile (top 25%) have a ROA % significantly above this median, while those in the bottom quartile fall well below. However, ROA % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Pro Medicus's current ROA % of 78.49% is 4385.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROA % mean?
A high ROA % can signal that a stock is expensive relative to its fundamentals. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on Pro Medicus and its competitors. For the Healthcare Providers & Services industry, the median ROA % is 1.75 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Pro Medicus's current ROA % is 78.49%, which is 202% above median its own 10-year median of 25.99. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pro Medicus stock overvalued right now?
Based on GuruFocus' analysis, Pro Medicus (ASX:PME) is currently considered Modestly Undervalued. The stock's GF Value™ is A$244.95, compared to a current price of A$185.39 — trading 24.3% below its estimated fair value. The current ROA % is 78.49%, which is 202% above median its 10-year median of 25.99 and 4385.1% above the Healthcare Providers & Services industry median of 1.75. Pro Medicus' overall GF Score™ is 98/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROA % calculated?
ROA % is calculated from a company's financial statements. For Pro Medicus (ASX:PME), the current ROA % is 78.49% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Pro Medicus (ASX:PME) Overvalued in 2026?
Based on GuruFocus' analysis, Pro Medicus stock appears to be undervalued.
The current stock price of A$185.39 is trading 24.3% below its estimated GF Value™ of A$244.95.
GuruFocus considers Pro Medicus to be Modestly Undervalued.
Key valuation signals for ASX:PME:
ROA %: 78.49% (202% above median its 10-year median of 25.99)
GF Value™: A$244.95 vs. price of A$185.39 (24.3% below fair value)
Industry Position: 4385.1% above the Healthcare Providers & Services median (#3 of 686)
No single metric tells the full story. See the ASX:PME stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Pro Medicus is a healthcare IT company specializing in radiology imaging software. Its main product, Visage 7, is a clinical desktop application that radiologists use to view, enhance, and manipulate images from any device and make a diagnosis. Its main customers are US private academic hospitals. In fiscal 2025, Pro Medicus earned 90% of revenue in North America, 8% from Australia, and the remaining 2% in Europe.
98GF Score
Get the complete analysis for ASX:PME
ROA % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:PME has been successfully added to your 
